UPDATE: Leerink Partners Downgrades Intra-Cellular Therapies (ITCI) to Market Perform

May 2, 2017 6:21 AM EDT
Get Alerts ITCI Hot Sheet
Price: $34.14 -1.04%

Rating Summary:
    15 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(Updated - May 2, 2017 7:29 AM EDT)

(updated to add analyst comment)

Leerink Partners downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Outperform to Market Perform, price target $10.00 (from $29.00).

ANalyst Seamus Fernandez comments "We are downgrading shares of ITCI to Market Perform following the corporate update highlighting an unusual preclinical safety concern for lumateperone (ITI-007), its atypical antipsychotic for the treatment of schizophrenia."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $10.49 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

The Children's Investment Fund (TCI)